Impax Asset Management Group plc Acquires 213,052 Shares of Enfusion, Inc. (NYSE:ENFN)

Impax Asset Management Group plc increased its holdings in shares of Enfusion, Inc. (NYSE:ENFN) by 31.5% during the 4th quarter, HoldingsChannel reports. The fund owned 890,000 shares of the company’s stock after buying an additional 213,052 shares during the period. Impax Asset Management Group plc’s holdings in Enfusion were worth $9,167,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the company. New York State Common Retirement Fund raised its holdings in Enfusion by 23.8% in the fourth quarter. New York State Common Retirement Fund now owns 1,926,968 shares of the company’s stock worth $19,848,000 after buying an additional 370,498 shares during the last quarter. Rhumbline Advisers raised its holdings in Enfusion by 3.0% in the fourth quarter. Rhumbline Advisers now owns 62,464 shares of the company’s stock worth $643,000 after buying an additional 1,796 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Enfusion by 612.4% in the third quarter. JPMorgan Chase & Co. now owns 208,022 shares of the company’s stock worth $1,974,000 after buying an additional 178,821 shares during the last quarter. Barclays PLC raised its holdings in Enfusion by 251.4% in the third quarter. Barclays PLC now owns 86,039 shares of the company’s stock worth $817,000 after buying an additional 61,554 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Enfusion by 7.3% in the third quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company’s stock worth $9,770,000 after buying an additional 70,367 shares during the last quarter. 81.05% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Enfusion news, COO Neal Pawar sold 21,801 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $10.03, for a total transaction of $218,664.03. Following the completion of the sale, the chief operating officer now directly owns 1,143,544 shares of the company’s stock, valued at approximately $11,469,746.32. This represents a 1.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Oleg Movchan sold 2,771 shares of the company’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total transaction of $28,070.23. Following the sale, the chief executive officer now directly owns 526,702 shares of the company’s stock, valued at approximately $5,335,491.26. This represents a 0.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 57,367 shares of company stock valued at $591,335 over the last three months. Insiders own 36.44% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on ENFN shares. William Blair reaffirmed a “market perform” rating on shares of Enfusion in a report on Monday, January 13th. Stifel Nicolaus lifted their target price on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th. Finally, Piper Sandler lifted their target price on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a report on Monday, December 23rd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, Enfusion has a consensus rating of “Hold” and an average price target of $10.50.

Enfusion Stock Down 0.4 %

ENFN opened at $11.46 on Tuesday. The firm has a 50 day moving average price of $10.84 and a 200-day moving average price of $9.69. Enfusion, Inc. has a twelve month low of $7.83 and a twelve month high of $11.80. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of 286.45, a PEG ratio of 1.85 and a beta of 0.96.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.